Polaris Venture Partners V amends Invivyd stake
Ticker: IVVD · Form: SC 13D/A · Filed: Dec 12, 2024 · CIK: 1832038
| Field | Detail |
|---|---|
| Company | Invivyd, INC. (IVVD) |
| Form Type | SC 13D/A |
| Filed Date | Dec 12, 2024 |
| Risk Level | medium |
| Pages | 14 |
| Reading Time | 17 min |
| Key Dollar Amounts | $0.0001, $0.6104, $91,560.00, $0.5886, $103,005.00 |
| Sentiment | neutral |
Sentiment: neutral
Topics: ownership-change, amendment, venture-capital
TL;DR
Polaris Venture Partners V just filed an amendment on Invivyd (formerly Adagio), watch this space.
AI Summary
On December 12, 2024, Polaris Venture Partners V, L.P. filed an SC 13D/A amendment regarding Invivyd, Inc. (formerly Adagio Therapeutics, Inc.). The filing indicates a change in beneficial ownership, with Polaris Venture Partners V, L.P. and its associated entities now holding a significant stake in Invivyd, Inc. The filing does not specify a dollar amount for the stake but details the group members involved in the filing.
Why It Matters
This filing signals a potential shift in control or influence for Invivyd, Inc. as a major venture capital firm updates its holdings.
Risk Assessment
Risk Level: medium — Changes in significant beneficial ownership can lead to shifts in company strategy or potential activist involvement.
Key Players & Entities
- Polaris Venture Partners V, L.P. (company) — Filing entity
- Invivyd, Inc. (company) — Subject company
- Adagio Therapeutics, Inc. (company) — Former name of subject company
- Jonathan Flint (person) — Group member
- Terrance McGuire (person) — Group member
FAQ
What is the specific percentage of Invivyd, Inc. shares beneficially owned by Polaris Venture Partners V, L.P. and its group members?
The filing does not explicitly state the exact percentage of shares beneficially owned, but it is an amendment to a Schedule 13D, indicating a significant stake.
When was the last time Polaris Venture Partners V, L.P. filed a Schedule 13D/A for Invivyd, Inc. prior to this amendment?
This filing is an amendment (SC 13D/A) filed on December 12, 2024, implying previous filings or a change from a prior state of ownership.
What is the primary business of Invivyd, Inc.?
Invivyd, Inc. is in the business of Biological Products (No Diagnostic Substances), with SIC code 2836.
Who are the key individuals listed as group members in this filing?
The key individuals listed as group members are Jonathan Flint and Terrance McGuire.
What was Invivyd, Inc. formerly known as?
Invivyd, Inc. was formerly known as Adagio Therapeutics, Inc., with a name change date of November 12, 2020.
Filing Stats: 4,196 words · 17 min read · ~14 pages · Grade level 11.7 · Accepted 2024-12-12 16:39:09
Key Financial Figures
- $0.0001 — INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class o
- $0.6104 — t a weighted average price per share of $0.6104 for aggregate proceeds of approximately
- $91,560.00 — for aggregate proceeds of approximately $91,560.00. On December 10, 2024, Polaris IX sol
- $0.5886 — t a weighted average price per share of $0.5886 for aggregate proceeds of approximately
- $103,005.00 — for aggregate proceeds of approximately $103,005.00. On December 11, 2024, Polaris IX sol
- $0.5911 — t a weighted average price per share of $0.5911 for aggregate proceeds of approximately
- $94,812.44 — for aggregate proceeds of approximately $94,812.44. SIGNATURE After reasonable inquiry
Filing Documents
- d896430dsc13da.htm (SC 13D/A) — 191KB
- 0001193125-24-277124.txt ( ) — 193KB
of the Original Schedule 13D is hereby amended and restated in its entirety as set forth below
Item 1 of the Original Schedule 13D is hereby amended and restated in its entirety as set forth below: This joint statement on Schedule 13D (this Statement ) is filed with respect to the common stock, par value $0.0001 per share ( Common Stock ), of Invivyd, Inc. (previously known as Adagio Therapeutics, Inc.), a Delaware corporation (the Issuer ). The address of the principal executive offices of the Issuer is 1601 Trapelo Road, Suite 178, Waltham, MA 02451. Item2. Identity and Background.
(b) of the Original Schedule 13D is hereby amended and restated in its entirety as set forth below
Item 2(b) of the Original Schedule 13D is hereby amended and restated in its entirety as set forth below: (b) The address of the principal offices of each Reporting Entity and the business address of each Reporting Individual is One Marina Park Drive, 8 th Floor, Boston, MA 02210. Item5. Interest in Securities of the Issuer.
of the Original Schedule 13D is hereby supplemented and amended, as follows
Item 5 of the Original Schedule 13D is hereby supplemented and amended, as follows: (a) and (b) See Items 7-11 and 13 of the cover pages of this Amendment No. 4. (c) On December 9, 2024, Polaris IX sold 150,000 shares of Common Stock at a weighted average price per share of $0.6104 for aggregate proceeds of approximately $91,560.00. On December 10, 2024, Polaris IX sold 175,000 shares of Common Stock at a weighted average price per share of $0.5886 for aggregate proceeds of approximately $103,005.00. On December 11, 2024, Polaris IX sold 160,400 shares of Common Stock at a weighted average price per share of $0.5911 for aggregate proceeds of approximately $94,812.44. SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated: December 12, 2024 POLARIS VENTURE PARTNERS V, L.P. By: Polaris Venture Management Co. V, L.L.C. By: * Authorized Signatory POLARIS VENTURE PARTNERS ENTREPRENEURS FUND V, L.P. By: Polaris Venture Management Co. V, L.L.C. By: * Authorized Signatory POLARIS VENTURE PARTNERS FOUNDERS FUND V, L.P. By: Polaris Venture Management Co. V, L.L.C. By: * Authorized Signatory POLARIS VENTURE PARTNERS SPECIAL FOUNDERS FUND V, L.P. By: Polaris Venture Management Co. V, L.L.C. By: * Authorized Signatory POLARIS VENTURE MANAGEMENT CO. V, L.L.C. By: * Authorized Signatory POLARIS PARTNERS IX, L.P. By: Polaris Partners GP IX, L.L.C. By: /s/ Lauren Crockett Name: Lauren Crockett Title: General Counsel POLARIS PARTNERS GP IX, L.L.C. By: /s/ Lauren Crockett Name: Lauren Crockett Title: General Counsel POLARIS HEALTHCARE TECHNOLOGY OPPORTUNITIES FUND, L.P. By: Polaris Healthcare Technology Opportunities Fund GP, L.L.C. By: /s/ Lauren Crockett Name: Lauren Crockett Title: General Counsel POLARIS HEALTHCARE TECHNOLOGY OPPORTUNITIES FUND